Related Experiment Video
Updated: Mar 25, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
18.7K
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Debra H Josephs1, Debashis Sarker1
1Department of Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK.
Translational Oncogenomics
|February 27, 2016
Summary
This review examines pharmacodynamic biomarkers for phosphatidylinositol 3-kinase (PI3K) pathway inhibitors in cancer clinical trials. It highlights challenges and strategies for integrating these biomarkers for personalized cancer medicine.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates critical cellular functions like growth and metabolism.
- Aberrant PI3K pathway activation due to mutations is common in various cancers.
- Targeted therapies inhibiting the PI3K pathway are under development for cancer treatment.
Purpose of the Study:
- To review pharmacodynamic biomarkers used in early-phase clinical trials of PI3K pathway inhibitors.
- To discuss challenges in developing and interpreting these biomarkers.
- To explore strategies for integrating biomarkers in personalized cancer medicine.
Main Methods:
- Literature review of early-phase clinical trials involving PI3K pathway inhibitors.
- Analysis of pharmacodynamic biomarker assays and their application.
- Discussion of biomarker integration with pharmacokinetic and predictive markers.
Main Results:
- Pharmacodynamic biomarkers are crucial for assessing PI3K inhibitor efficacy and target engagement.
- Challenges include assay development, validation, and interpretation of results.
- Successful integration requires combining pharmacodynamic, pharmacokinetic, and predictive biomarkers.
Conclusions:
- Effective pharmacodynamic biomarkers are essential for advancing PI3K pathway inhibitors in oncology.
- Overcoming challenges in biomarker development and interpretation is key.
- A personalized medicine approach, integrating multiple biomarker types, will optimize PI3K inhibitor therapy for cancer patients.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
6.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.2K
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
111
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
111
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
73
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
73
01:27Pharmacodynamic Models: Overview
78
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
78
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
64
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
64